AB&B BIO-TECH-B (02627) announced that the National Medical Products Administration (NMPA) of China has approved the new drug application for the Group's trivalent influenza virus subunit vaccine intended for all age groups.
As of the date of this announcement, this vaccine has become the first and only fully-population, full-dose trivalent influenza virus subunit vaccine approved for marketing in China.
The product represents a significant upgrade over traditional split-virus vaccines, offering advantages such as comprehensive protection, high purity of component antigens, and a lower risk of adverse reactions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments